



## ORIGINAL RESEARCH ARTICLE

# Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients

Chitrabhanu Ballav<sup>1</sup> | Archana Dhere<sup>1</sup> | Irene Kennedy<sup>2</sup> | Olorunsola F. Agbaje<sup>2</sup> | Sarah White<sup>1,3</sup> | Rachel Franklin<sup>1,3</sup> | Bolette Hartmann<sup>4</sup> | Jens J. Holst<sup>4</sup> | Rory R. Holman<sup>2,3</sup> | Katharine R. Owen<sup>1,3</sup>

<sup>1</sup>Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK

<sup>2</sup>Diabetes Trials Unit, University of Oxford, Oxford, UK

<sup>3</sup>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals, Oxford, UK

<sup>4</sup>NNF Center for Basic Metabolic Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

## Correspondence

Chitrabhanu Ballav, Stoke Mandeville Hospital, Mandeville Road, Aylesbury HP21 8AL, UK.

Email: c.ballav@nhs.net

## Funding information

Sanofi Aventis, UK Research grant; University of Oxford; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)

## Abstract

**Aims:** The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D).

**Methods:** In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4–10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15).

**Results:** PPBG CGM readings in target were similar between L vs P (Mean %  $\pm$  SE, breakfast  $45.4 \pm 6.0$  vs  $44.3 \pm 6.0$ ,  $P = .48$ , lunch  $45.5 \pm 5.8$  vs  $50.6 \pm 5.3$ ,  $P = .27$  and dinner  $43.0 \pm 6.7$  vs  $47.7 \pm 5.6$ ,  $P = .30$ ). HbA1C was similar between L vs P ( $64.7 \pm 1.6$  vs  $64.1 \pm 1.6$  mmol/mol,  $P = .30$ ). Prandial insulin fell after lixisenatide (dose change  $-0.7 \pm 0.6$  vs  $+2.4 \pm 0.7$  units/d,  $P = .004$ ), but basal insulin dose was similar between groups. The post-MMT glucose area under the curve (AUC) was lower with L than P ( $392.0 \pm 167.7$  vs  $628.1 \pm 132.5$  mmol/L  $\times$  min,  $P < .001$ ), as was the corresponding glucagon AUC ( $140.0 \pm 110.0$  vs  $304.2 \pm 148.2$  nmol/L  $\times$  min,  $P < .001$ ). Glucagon and counter-regulatory hormone values at a blood glucose of 2.4 mmol/L during the hypoglycaemic clamp were similar between L and P.

**Conclusion:** In T1D, PPBG values were not altered by adjunctive lixisenatide although prandial insulin dose fell. Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.

## KEYWORDS

GLP1 analogue, lixisenatide, type 1 diabetes

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Endocrinology, Diabetes & Metabolism* published by John Wiley & Sons Ltd.

## 1 | INTRODUCTION

Only 30% of patients with type 1 Diabetes (T1D) achieve a glycaemic goal of HbA1C <7.5% (58 mmol/mol).<sup>1</sup> Post-prandial hyperglycaemia is common in all types of diabetes and may have a role in overall glycaemic control.<sup>2</sup> It is generally agreed that reducing glucose excursion after meal improves overall glycaemic control,<sup>3</sup> although recent reviews have cast a doubt on the effect of short glucose variability on long-term diabetes complications.<sup>4</sup>

Glucagon levels are physiologically suppressed at high plasma glucose concentrations. In the absence of diabetes and in T2D, glucagon level is found to be higher after oral glucose compared with isoglycaemic intravenous glucose infusion, although more insulin is secreted when glucose is administered by the oral route. This has been attributed to the glucagonotropic effect of GIP.<sup>5</sup> In people with T1D with no detectable  $\beta$  cell function, paradoxically high levels of glucagon have been noticed after 50 g oral glucose compared with isoglycaemic glucose infusion.<sup>6</sup> Post-prandial hyperglucagonaemia following a MMT has been found to worsen progressively in the first year after a new diagnosis of T1D, as C-peptide levels decline.<sup>7,8</sup> Nonsuppression of glucagon contributes to post-prandial hyperglycaemia in T1D and therefore may have a role in treatment.

The short-acting exendin-based glucagon-like peptide-1 (GLP1) receptor agonist lixisenatide reduces post-prandial hyperglycaemia by suppressing glucagon, and by slowing gastric emptying<sup>9</sup> in T2D. In this study, we investigate its effect in patients with T1D.

## 2 | MATERIALS AND METHODS

### 2.1 | Study design

A single centre, double blind, placebo-controlled crossover trial was performed (Figure 1). Patients were enrolled from the outpatient clinic at the Oxford Centre for Diabetes Endocrinology and Metabolism. The study was approved by the clinical ethics

committee of UK, registered with ISCRTN (No. 00290196), performed according to Good Clinical Practice and externally monitored. Following informed consent, participants were randomised by a computer-generated programme to receive treatment for 4 weeks with lixisenatide (10  $\mu$ g/d titrated up to 20  $\mu$ g/d in 2 weeks if tolerated) or placebo in the morning, along with their usual insulin, in random order with a washout period of 4 weeks between treatments. During the treatment period, the usual dose of insulin was reduced ( $\sim$ 20% basal insulin,  $\sim$ 50% bolus at breakfast, and  $\sim$ 20% bolus at lunch). Participants were advised on insulin titration to maintain blood glucose between 6 and 9 mmol/L, guided by investigators. They received a phone call at the beginning of week 3 to check on side effects, and to advise titration of the trial drug to 20  $\mu$ g/d. They were advised to follow their usual daily routine.

Participants underwent continuous glucose monitoring (CGM) with Navigator, Abbott Diabetes Care for 3-5 days at the beginning and before the end of the treatment period. Standardised advice on calibration and hypoglycaemia avoidance were provided. Patients maintained a diary of meal times during this period, and data for first 72 hours of CGM were used for analysis of the primary end-point, defined as proportion of CGM readings between 4 and 10 mmol/L in the 3 hours post-prandial period following the three major meals (breakfast, lunch and evening meal). At the final 2 days of treatment period, patients were given the option to have a standardised mixed-meal test (MMT) and a hyperinsulinaemic-hypoglycaemic clamp (clamp).

Secondary end-points included comparison between changes in insulin doses between treatment groups, and end-points after MMT and Clamp. The MMT (240 mL Fortisip liquid containing 18.4 g carbohydrate/100 mL) was performed in the penultimate day of each treatment period, in the morning after overnight fast, and 20 minutes after their blinded study medication. No prandial insulin was provided. Glucose and glucagon concentrations were measured at baseline and every 30 minutes for 2 hours between treatment groups.

The clamp was performed in the final day of the treatment period, in the morning after overnight fast, and 20 minutes after





FIGURE 1 Trial design

**FIGURE 2** Screening, randomisation and retention

their blinded study medication. Participants with a high blood glucose level (10–15 mmol/L) were given intravenous insulin to reduce their blood glucose to 10 mmol/L. Participants received a primed, continuous infusion of insulin (Actrapid) at 3.0 mU/kg/min from 0 to 4 minutes, 2.5 mU/kg/min from 4 to 7 minutes, 2.0 mU/kg/min from 7 to 10 minutes and 1 mU/kg/min thereafter, with 20% glucose infused at a variable rate to achieve three steps of glycaemic plateau of 7.5 mmol/L of glucose (time 0–45 minutes), the second, euglycaemic at 5.0 mmol/L (to reach 5.0 mmol/L between 45 and 90 minutes and maintain a plateau of 5.0 mmol/L for 90–135 minutes) and the third, hypoglycaemic at 2.5 mmol/L (to reach 2.5 mmol/L between 135 and 180 minutes and maintain a plateau of 2.5 mmol/L for 180–225 minutes). After the hypoglycaemic step, the insulin infusion was discontinued and glucose was infused if necessary to allow recovery of blood glucose to more than 4 mmol/L at least on two readings. The rates of glucose infusion were adjusted according to established algorithms, guided by real-time glucose measurements taken at the bed side (1 mL/measurement) every 5 minutes and measured by the glucose dehydrogenase technique using a HemoCue device (HemoCue). The procedure was performed with patients in supine position, and samples for glucose and glucagon were collected every 15 minutes for 225 minutes. Other counter-regulatory hormones (adrenaline, noradrenaline, cortisol and pancreatic polypeptide) were sampled during the hypoglycaemic phase, between 180 and 225 minutes.

## 2.2 | Laboratory measurements

Electrolytes and glucose concentrations were measured at the CPA-accredited Oxford University Hospitals NHS Trust biochemistry laboratory (ADVIA 2400 general chemistry analyser). C-peptide and cortisol were analysed using chemiluminescence

immunoassay (ADVIA Centaur analyser using Siemens Healthcare Diagnostics Ltd.). HbA1C was measured using ion-exchange chromatography (Menarini 8160 Diagnostics). Adrenaline, noradrenaline and pancreatic polypeptide were measured using ELISA. Glucagon was measured using a sandwich ELISA, which uses antibodies to both C- and N- terminal antglucagon antibodies, and eliminates cross-reactivity with elongated or truncated forms of glucagon peptide.<sup>10</sup>

## 2.3 | Statistical analysis


The sample size was calculated based on the percentage of readings between 4 and 10 mmol/L derived using CGM for 3 hours post-prandial period. As no data were available for lixisenatide in any previous cohort, best estimates derived from similar data sets<sup>11</sup> have been used for our power calculation. The mean of the

**TABLE 1** Key baseline characteristics in mean (SD)

Baseline characteristics	Mean (SD)
Females	13
Age (y)	44 (2.5)
Duration of diabetes (y)	18.6 (14.2)
Insulin (basal U/d)	27.32 (15.1)
Insulin (prandial U/d)	18.28 (14.3)
FPG (mmol/L)	10.2 (4.5)
C-peptide (nmol/L)	0.03 (0.04)
Creatinine (μmol/L)	70.46 (15.81)
eGFR (mL/min/1.73 m <sup>2</sup> )	84.58 (11.3)
Bilirubin (μmol/L)	11.81 (5.01)
ALT (IU/L)	20.96 (10.26)
ALP (IU/L)	107.2 (57.28)

	Lixisenatide	Placebo	P value
Baseline HbA1C (DCCT: %)	7.9 (0.5)	7.9 (0.5)	.99
HbA1C after treatment (DCCT: %)	8.1 (1.0)	8.0 (0.5)	.78
Baseline HbA1C (IFCC: mmol/mol)	63.8 (8.0)	63.9 (8.0)	.93
HbA1C after treatment (IFCC: mmol/mol)	64.7 (8.5)	64.1 (8.0)	.8
Difference in HbA1C (DCCT: %)	0.07 (0.3)	0.03 (0.4)	.58
Difference in HbA1C (IFCC: mmol/mol)	0.92 (3.1)	0.13 (4.0)	.44
Baseline BMI (kg/m <sup>2</sup> )	27.0 (3.5)	27.1 (3.5)	.98
BMI after treatment (kg/m <sup>2</sup> )	26.6 (3.6)	27.1 (3.5)	.61
Difference in BMI (kg/m <sup>2</sup> )	-0.48 (0.4)	-0.08 (0.5)	.001
Baseline body weight (kg)	78.8 (11.1)	79.0 (11.2)	.99
Body weight after treatment (kg)	77.6 (11.0)	79.2 (11.1)	.63
Difference in body weight (kg)	-1.4 (1.1)	1.1 (1.7)	<.001

**TABLE 2** Effect of treatment on HbA1C, BMI, and body weight as mean (SD)



**FIGURE 3** A, Percentage of CGM readings within 4-10 mmol/L before and after treatment and between groups. B, Change in insulin dose between groups. Values in mean (SEM)

primary outcome and the within-patient standard deviation in the targeted population was estimated to be 55.3% and 13.7%, respectively, using data published from a randomised controlled trial of 91 insulin-requiring patients (75 with type 1 and 16 with type 2 diabetes). Using a significance level (alpha value) of .05 and allowing a 10% drop out rate, a sample size of 30 patients would provide a 90% power to detect a 15% increase in the primary

outcome, defined as a beneficial effect of lixisenatide on post-prandial glucose levels of CGM.

Data are expressed in means  $\pm$  SD or SEM. Baseline data are represented as mean (SD), when values are compared between treatment and placebo arms mean (SEM) has been used. Normally distributed data were compared using the Student's *t* test (paired within and unpaired between groups). Nonparametric data were compared with Mann-Whitney *U* test between groups, and Wilcoxon test for paired differences within groups. Statistical significance was  $P < .05$ . Statistical analysis has been done on SPSS 22.

### 3 | RESULTS

#### 3.1 | Subjects and effect on baseline characteristics

Patients were recruited from outpatient clinics of Oxford University Hospitals NHS Trust by the investigators, from January 2014 to August 2016. Recruitment was closed after 30 subjects had been screened, and 27 were randomised (Figure 2). A total of 25 participants completed the trial as two stopped after the first treatment period (one who became pregnant, and one who withdrew consent). Baseline characteristics of the participants are summarised in Table 1.

There was no difference in mean HbA1c after treatment between lixisenatide or placebo. There was no difference in mean BMI or body weight when comparing groups, before or after treatment. However while the body weight did not change after treatment with placebo, a small but significant reduction was noticed after lixisenatide (Table 2).

#### 3.2 | Primary end-point

Continuous glucose monitoring data were analysed in all 25 data sets. After excluding incomplete data, comparison between groups

pre-treatment was between 25 data sets, while comparison between pre- and post-treatment and between groups post-treatment was in 22 data sets. The mean percentage of CGM readings in target range (4–10 mmol/L) during the 3 hours after meals in range were similar before and after treatment, and between lixisenatide and placebo for all meals (Mean [SEM]: Breakfast 45.4 [6.0] % vs 44.3 [6.0] %,  $P = .9$ , lunch 45.5 [5.8] % vs 50.6 [5.3] %,  $P = .6$  and dinner 43.0 [6.7] % vs 47.7 [5.6] %,  $P = .6$ ; Figure 3A, Table S1).


### 3.3 | Insulin requirement

There was a numerically lower total basal insulin dose after treatment in both groups, with a greater reduction seen after lixisenatide (26.6 [2.8] U/d to 21.4 [1.9] U/d after lixisenatide,  $P = .4$ , and 27.2 [3.0] U/d to 23.3 [2.3] U/d after placebo,  $P = .6$ ); however, this was not significant between groups before or after treatment (Figure 3B, Table S1). The total prandial insulin was numerically lower after treatment with lixisenatide (19.0 [3.0] U/d to 18.4


[2.9] U/d,  $P = .1$ ) and numerically higher after treatment with placebo (18.3 [2.9] U/d to 20.5 [3.0] U/d,  $P = .06$ ), resulting in a significantly lower total prandial insulin dose after treatment with lixisenatide compared with placebo. This drop in prandial insulin dose with treatment was most prominent after breakfast (Figure 3B, Table S1).

### 3.4 | Mixed meal test

All 25 patients participated in the meal tolerance test for 120 minutes, and 18 of them had the test extended by another hour to 180 minutes. Mean plasma glucose level after the lixisenatide treatment period expressed as Mean (SEM) was 11.2 (0.8) mmol/L at baseline, increasing to 13.0 (1.0) mmol/L at 120 minutes and 13.6 (1.4) mmol/L at 180 minutes. Glucose levels after placebo were 11.5 (0.9) mmol/L at baseline ( $P = .48$  vs lixisenatide) and increased at 120 minutes to 21.3 (0.7) mmol/L ( $P < .001$ ) and at 180 minutes to 20.0 (1.1) mmol/L ( $P = .001$ ).



**FIGURE 4** A, Blood glucose level after standardised mixed meal. B, Blood glucagon level after standardised mixed meal. Values in mean (SEM)



**FIGURE 5** A, Blood glucose level during hyperinsulinaemic hypoglycaemic clamp between groups. B-E, Counter-regulatory hormone levels during the hypoglycaemic phase between groups. Values in mean (SEM)

Corresponding glucagon level after lixisenatide at baseline was 5.8 (0.7) pmol/L and reduced at 120 minutes to 4.5 (0.5) pmol/L, and at 180 minutes to 4.5 (0.8) pmol/L. In contrast, glucagon level after placebo was 6.5 (0.6) pmol/L ( $P = .44$  vs lixisenatide) at baseline and increased at 120 minutes to 9.5 (0.8) pmol/L

( $P < .001$ ) and then settled at 180 minutes to 6.7 (1.0) pmol/L ( $P = .09$ ) (Figure 4A, Table S2). The AUC at 120 minutes for glucose was 392.0 (167.7) mmol/L  $\times$  min after lixisenatide and 628.1 (132.5) mmol/L  $\times$  min after placebo ( $P < .001$ ). The AUC at 120 minutes for glucagon was 140.0 (110.0) nmol/L  $\times$  min

**TABLE 3** Number of adverse events reported by patients during 4 wk of treatment compared to the week prior to the treatment

Treatment	Hypoglycaemia	Gastrointestinal side effects	Headache	Diabetes eye complications	Infections	Loss of consciousness	Pregnancy	Nonspecific	Total
Lixisenatide	298	12	5	1	2	0	0	2	320
Placebo	421	2	1	2	5	1	1	3	436
Pretreatment	84	0	0	0	0	0	0	0	84

after lixisenatide and 304.2 (148.2) nmol/L × min after placebo ( $P < .001$ ) (Figure 4, Table S2).

infections. There was no incidence of Diabetic Keto Acidosis during the trial.

### 3.5 | Hyperinsulinaemic hypoglycaemic clamp

A total of 15 patients agreed to undergo the hypoglycaemic clamps, but one individual only completed one clamp and so this data was excluded, leaving 14 paired clamps to be analysed. Mean plasma glucose level at the start of the clamp was the same between groups, and fell steadily during the clamp in both groups to euglycaemic level between 90 to 135 minutes (Figure 5A, Table S3). Hypoglycaemic threshold was reached between 180 and 225 minutes in both groups. Glucagon level was found to fall in both groups up to 180 minutes and then increased during hypoglycaemic phase (180–225 minutes) of the clamp. There was no significant difference in glucagon level during hypoglycaemia between groups. Other counter-regulatory hormones—adrenaline, noradrenaline, cortisol and pancreatic polypeptide (PP) increased during hypoglycaemia, but there was no significant difference between groups (Figure 5B–E, Table S3).

### 3.6 | Adverse events

A total of 840 adverse events were reported in 27 patients during the study (Table 3). One serious adverse event was reported during treatment with placebo, when loss of consciousness resulted in hospital attendance. Blood glucose testing at site confirmed that this was not related to hypoglycaemia. None of the adverse effects resulted in withdrawal from the study. Another participant became pregnant during treatment with placebo did not enter the lixisenatide arm and was excluded from the study.

The majority of the adverse events (95% of total) reported by participants related to hypoglycaemia (defined as capillary blood glucose  $<4$  mmol/L). Reported hypoglycaemic episodes in the pre-randomisation period were 84 accounting for 3.2 episodes per patient per week, 298 episodes during treatment with lixisenatide (2.9 episodes per patient per week) and 421 during treatment with placebo (4.1 episodes per patient per week). There were no reported episodes of severe hypoglycaemia.

Gastrointestinal side effects (nausea, vomiting, bloating and diarrhoea) were the next most commonly reported side effect, with 12 episodes were reported with lixisenatide and 2 episodes with placebo. Other common side effects were headache and minor

## 4 | DISCUSSION

In this first study with lixisenatide in patients with T1D, 4-week exposure to lixisenatide did not make significant difference to the pre-specified primary end-point of proportion of CGM readings within the defined range of 4–10 mmol/L in the post-prandial period. The dose of insulin was reduced at the start of treatment, and patients were advised to titrate the dose up to maintain their blood glucose level between 6 and 9 mmol/L. It was noticed that significantly less insulin was being used at the end of treatment period with lixisenatide to achieve a similar time in range after meals. As expected the insulin dose could be reduced most at breakfast and did not change with the evening meal when the effect of lixisenatide may have declined. Although patients only had treatment for 4 weeks, there was significant reduction in mean body weight after treatment with lixisenatide.

The most striking findings from our study were seen in the MMT, where lixisenatide was given, but not rapid insulin. We observed a large attenuation in glucose rise, accompanied by suppression of glucagon compared with the placebo group in the absence of prandial insulin. This reduction in PPBG was not seen during the 4-week treatment period, and we hypothesise that it is likely that most patients did not have enough time within the 4 weeks to fully intensify insulin treatment to achieve their usual glycaemic goals. This could explain why the proportion of post-prandial blood glucose levels in the euglycaemic range was comparable between groups, despite a lower prandial insulin dose. This could be tested in trials with longer exposure to lixisenatide. The effect of lixisenatide on slowing down gastric emptying may significantly contribute to its effect on PPBG. This is less likely to be seen in longer-acting GLP1 analogues like liraglutide as the effect on gastric emptying may be blunted over time, owing to tachyphylaxis. This study did not examine gastric emptying with lixisenatide.

The clamp study also demonstrated that although glucagon level was reduced in the post-prandial period, there was no significant effect on counter-regulatory hormone level during hypoglycaemia during treatment with lixisenatide. The safety of lixisenatide in T1D patients was established, and there was less patient reported hypoglycaemia during treatment with lixisenatide than placebo. In line with other trials involving GLP1 receptor agonists, there was higher incidence of gastrointestinal side effects during treatment with lixisenatide compared with placebo.

Our findings are consistent with previous studies investigating the effect of GLP1 receptor agonist liraglutide in people with T1D.<sup>12</sup> In the first trial with liraglutide, 4-week treatment did not make any difference to glucose levels, although reduced insulin requirement was observed. In longer trials, liraglutide was found to result in small but significant improvement in HbA1C level after 12, 26 and 52 weeks treatment.<sup>13-15</sup> In our trial, similar to liraglutide,<sup>12</sup> the dose of insulin was significantly reduced at the start of the treatment to avoid risk of hypoglycaemia.

This study comprehensively investigates the effect of lixisenatide on post-prandial blood glucose in a real life setting, as well as experimental conditions.

In summary, our study raises the possibility that in selected patients, a short-acting GLP-1 receptor agonist could be a useful adjunctive treatment in T1D to limit post-prandial glucose rise.

## ACKNOWLEDGEMENTS

This investigator- initiated study was sponsored by the University of Oxford and funded by Sanofi via research grant. We thank Prof S.C.L. Gough for conceptualising the study, and also for his significant input into writing the protocol for this study. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. We thank Prof R.R. Holman, who is an emeritus UK National Institute for Health Research Senior Investigator for his oversight of the trial.

## CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

## AUTHOR CONTRIBUTIONS

Chitrabhanu Ballav conceived and designed the study under supervision of Prof SCL Gough (see above), recruited and consented subjects, performed the experiments (CGM, Mixed Meal Test, and Clamp), analysed the data and drafted the manuscript. Archana Dhere recruited and consented subjects, performed the experiments and analysed the data. Irene Kennedy helped with analysis of data and contributed to drafting the manuscript. Olorunsola Agbaje performed the statistical analysis on primary end-point and contributed to drafting the manuscript. Sarah White and Rachel Franklin performed key study visits, performed the experiments, and contributed to drafting the manuscript. Bolette Hartmann analysed samples from the study and contributed to drafting the manuscript. Jens J. Holst offered advice on designing the study, analysed samples from the study and contributed to drafting the manuscript. Rury R. Holman offered advice on designing the study, had oversight on performing the study and analysis of results and contributed to drafting the manuscript. Katharine R. Owen was the head oversight over designing and performing the study, analysis of the results and supervised the drafting of the manuscript.

## ETHICAL APPROVAL

The study was performed in accordance with good clinical practice and was approved by the clinical ethics committee in UK (ISRCTN No. 00290196). Patients were recruited from outpatient clinics at the Oxford Centre for Diabetes, Endocrinology and Metabolism. Informed consent was obtained prior to participation, and the study was monitored by an external monitor.

## DATA AVAILABILITY STATEMENT

Individual participant data will not be available.

## ORCID

Chitrabhanu Ballav  <https://orcid.org/0000-0002-5723-2502>

Rury R. Holman  <https://orcid.org/0000-0002-1256-874X>

## REFERENCES

- Digital N. National Diabetes Audit, 2017-18 care processes and treatment targets short report; 2018.
- Brod M, Pfeiffer KM, Barnett AH, Berntorp K, Vilsboll T, Weissenberger B. Perceptions of diabetes control among people with type 2 diabetes treated with basal insulin in Sweden, Switzerland, and the United Kingdom. *Curr Med Res Opin*. 2016;32:1653-1661.
- Federation ID. *Guideline for Management of Post Meal Glucose in Diabetes*. 2011. [www.idf.org](http://www.idf.org). Accessed February 16, 2020.
- Livingstone R, Boyle JG, Petrie JR. How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with type 1 diabetes? *Diabet Med*. 2020;37:513-521.
- Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. *Diabetologia*. 2007;50(4):806-813.
- Hare KJ, Vilsboll T, Holst JJ, Knop FK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. *Am J Physiol Endocrinol Metab*. 2010;298(4):E832-E837.
- Brown RJ, Sinaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. *Diabetes Care*. 2008;31(7):1403-1404.
- Sherr J, Tsalikian E, Fox L, et al. Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosis. *Diabetes Care*. 2014;37(6):1741-1744.
- Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. *Diabetes Care*. 2015;38(7):1263-1273.
- Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: non-specific interference or truly elevated levels? *Diabetologia*. 2014;57(9):1919-1926.
- Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. *Diabetes Care*. 2006;29(1):44-50.
- Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. *Diabetes*. 2011;60(5):1599-1607.

13. Ahren B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. *Diabetes Care*. 2016;39(10):1693-1701.
14. Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. *Diabetes Care*. 2016;39(6):1027-1035.
15. Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. *Diabetes Care*. 2016;39(10):1702-1710.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Ballav C, Dhere A, Kennedy I, et al. Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. *Endocrinol Diab Metab*. 2020;3:e00130. <https://doi.org/10.1002/edm2.130>